Curated News
By: NewsRamp Editorial Staff
September 17, 2026
Telomir-Zn Shows Promise in AMD Preclinical Study
TLDR
- Telomir Pharmaceuticals' Telomir-Zn shows preclinical success in AMD, offering a competitive edge in epigenetic therapeutics and a clear path to oncology trials.
- Telomir-Zn reduces oxidative stress and restores DNA methylation, inhibiting iron-dependent demethylases, as published in the International Journal of Molecular Sciences.
- Telomir Pharmaceuticals' research offers hope for improved vision and quality of life for AMD patients, potentially transforming treatment landscapes.
- Telomir-Zn restored vision in AMD models by altering DNA methylation and telomere length, showcasing epigenetic therapy's unexpected potential.
Impact - Why it Matters
This news matters because it highlights a potential breakthrough in treating age-related macular degeneration, a leading cause of vision loss, while also advancing understanding of epigenetic regulation in disease. Telomir's dual focus on AMD and triple-negative breast cancer underscores the broad therapeutic potential of targeting metal homeostasis and epigenetic pathways. Positive preclinical results not only bolster the company's scientific credibility but also open avenues for novel treatments in oncology and beyond. For investors, this could signal a promising pipeline and future value, while patients may eventually benefit from innovative therapies for currently hard-to-treat conditions.
Summary
Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company, announced the peer-reviewed publication of preclinical research in the International Journal of Molecular Sciences showing that its lead candidate Telomir-Zn significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (AMD). The study also found that treatment was associated with restoration of altered DNA methylation patterns and a dose-dependent increase in relative telomeric DNA content toward levels observed in healthy animals, suggesting a potential epigenetic mechanism of action.
The findings further revealed that Telomir-Zn reduced intracellular labile iron and inhibited iron-dependent Jumonji C histone demethylases, providing a potential mechanistic link between intracellular metal modulation and epigenetic regulation. Despite these promising preclinical results in AMD, Telomir emphasized that its clinical development remains focused on oncology. Telomir-Zn is advancing under an FDA-cleared Investigational New Drug application for a Phase 1/2 trial in patients with advanced or metastatic triple-negative breast cancer. The company’s focus on epigenetic and metabolic drivers of cancer underscores its strategic commitment to addressing unmet needs in oncology.
For more details, the full press release is available at https://ibn.fm/iUtFx. Investors and stakeholders can find the latest updates on TELO in the company’s newsroom at https://ibn.fm/TELO. The announcement was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire and editorial syndication to 5,000+ outlets.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Telomir-Zn Shows Promise in AMD Preclinical Study
